Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. [Journal Article, Research Support, Non-U.S. Gov't]
J Heart Lung Transplant 2009 Mar; 28(3):280-4.
BACKGROUND: The aim of our study was to describe the efficacy of addition of intravenous or subscutaneous prostanoids in idiopathic pulmonary arterial hypertension (PAH) patients deteriorating on bosentan or on bosentan-sildenafil.
METHODS: PAH treatment at our hospital is standardized with first-line oral therapy in New York Heart Association class III patients followed by addition of prostanoids on clinical worsening.
RESULTS: Mean improvement in 6-minute walk distance after 4 months of prostanoids was 86 m (p < 0.01) in the bosentan group versus 41 m (p < 0.05) in the bosentan-sildenafil group, and these improvements persisted at long-term follow-up.
CONCLUSIONS: From these results we conclude that addition of subcutaneous or intravenous prostanoids can be efficacious in PAH deteriorating on oral therapy.
More from this journal |
